What Does a Positive MRSA Nasal Swab Mean?

A positive MRSA nasal swab means the bacterium methicillin-resistant Staphylococcus aureus is living in your nose, but it does not mean you have an active infection. The medical term for this is colonization: the bacteria have taken up residence without causing symptoms or tissue damage. Most people who carry MRSA in their nostrils never develop an infection from it, yet the finding still matters because it changes how doctors manage your care, especially before surgery or during a hospital stay.

Colonization Versus Infection

The distinction between carrying MRSA and being sick from it is the single most important thing to understand about a positive nasal swab. MRSA screening swabs are designed to detect patients who are colonized, not to diagnose active disease.¹ Colonization means the bacteria are present on your skin or mucous membranes in a stable way. You feel fine, you have no symptoms, and the bacteria are not invading your tissue. Infection, by contrast, means the bacteria have breached the body’s defenses and are causing harm: a wound that turns red and swollen, a bloodstream infection, pneumonia.

Colonization does matter, though, because it is a stepping stone toward infection in certain circumstances. Being colonized with MRSA is recognized as a key factor in the development of active MRSA infections, particularly in people who are about to undergo surgery, are immunocompromised, or are spending extended time in a hospital.² In one study of surgical patients, those who screened positive on a nasal PCR test had an MRSA surgical site infection rate roughly nine times higher than those who screened negative.³ Even so, the absolute rate among carriers in that study was under 2%, meaning more than 98 out of 100 colonized patients did not develop a surgical site infection.

How the Swab Is Tested

There are two main laboratory approaches used on a nasal swab, and the method affects how quickly you get results and how accurate they are. Culture-based methods, including newer chromogenic agar plates, involve growing the bacteria from the swab in a lab dish. These are reliable but slow. A chromogenic plate read at 18 to 24 hours catches about 78% of carriers, and waiting a full 48 hours pushes that to around 88%.⁴

PCR (polymerase chain reaction) tests look for MRSA DNA directly. They are faster and more sensitive, catching about 92% of carriers across pooled studies, with results sometimes available in under two hours.⁵ One head-to-head comparison reported PCR sensitivity of 100% against the chromogenic agar benchmark, with a turnaround time averaging about 14.5 hours in that lab’s workflow.⁶ The tradeoff is that PCR can occasionally produce a false positive. About 8% of PCR-positive nasal samples in one study yielded bacteria that were actually methicillin-susceptible; the PCR flagged a genetic element that resembled the resistance gene but did not actually confer resistance.⁷ If your positive result came from a rapid PCR and your care team orders follow-up culture, that false-positive possibility is the reason.

What a Negative Swab Tells Your Doctor

Ironically, a negative MRSA nasal swab is often more clinically useful than a positive one. The test’s negative predictive value for various MRSA infections is remarkably high. In pneumonia patients, a negative nasal swab rules out MRSA pneumonia with a negative predictive value around 97 to 99%.^{8 9} One study found the negative predictive value hit 100% for MRSA urinary tract infections and nearly 98% for both MRSA bloodstream infections and MRSA pneumonia.¹⁰

This matters for a practical reason: if you are admitted to the hospital with a suspected lung or bloodstream infection and your nasal swab comes back negative, your doctor can feel confident about not starting or continuing vancomycin, the heavy-hitting antibiotic typically used for MRSA. That keeps you from being exposed to a potent drug you likely do not need.

What a Positive Swab Tells Your Doctor

A positive swab is less definitive than a negative one. The positive predictive value for MRSA pneumonia is only about 35 to 45% in most hospital populations, and even in community and healthcare-associated pneumonia it only reaches about 57%.^{8 9} In other words, most people with a positive nasal swab who develop pneumonia do not actually have MRSA pneumonia. The swab tells doctors there is enough risk to warrant coverage, but it is a flag, not a diagnosis.

For surgical patients, the predictive power is more concerning. In surgical intensive care patients who screened positive on admission, subsequent MRSA-positive cultures were dramatically more common across every body site tested: lower respiratory tract, superficial wounds, deep wounds, tissue, and body fluids all showed substantially higher MRSA positivity rates compared to patients who screened negative on admission.¹¹ This is why a positive nasal swab before surgery triggers a decolonization protocol rather than a shrug.

How Vancomycin Use Changes Based on the Swab

One of the most tangible consequences of nasal swab results is what happens with vancomycin prescribing. Vancomycin is effective against MRSA but carries real risks, including kidney damage. In ICU patients, implementing a protocol where a negative nasal swab prompted doctors to stop vancomycin cut the median duration from about 2.6 days down to 1.4 days.¹² A systematic review pooling multiple studies found that nasal swab-guided protocols reduced vancomycin duration by roughly one day on average, with a trend toward fewer cases of kidney injury.¹³ Hospitals that actively encouraged providers to order nasal swabs and act on negative results saw sustained month-over-month reductions in vancomycin use.¹⁴

For you as a patient, this means the nasal swab result may directly determine which antibiotics you receive, for how long, and at what risk of side effects. If you are told your swab was negative, it is genuinely good news for your treatment plan.

Decolonization After a Positive Result

If you test positive, your medical team may prescribe a decolonization regimen to try to clear the MRSA before it can cause trouble. The standard approach combines mupirocin, an antibiotic ointment applied inside the nostrils, with chlorhexidine body washes.¹⁵ This is most commonly used before elective surgeries and at hospital discharge for known MRSA carriers.

The evidence behind this approach is fairly strong. In cardiac surgery patients, combining PCR screening with mupirocin nasal treatment and antiseptic body wash was associated with a 77% relative reduction in MRSA surgical site infections.¹⁶ In a large trial of MRSA carriers after hospital discharge, a decolonization protocol reduced the odds of MRSA colonization by more than half at one month, and the benefit persisted through nine months at most body sites.¹⁷ That same trial found the hazard of developing an MRSA infection dropped by about 30% in the decolonization group, with one infection prevented for every 30 patients treated.¹⁸

Decolonization is not permanent. MRSA can return, especially with ongoing risk factors like hospital readmissions. And there is a real concern about mupirocin resistance. Studies have found that after attempted decolonization, the proportion of MRSA isolates resistant to mupirocin roughly tripled.¹⁹ Another trial recorded new mupirocin resistance emerging in about 10% of patients.²⁰ This is a genuine tension in the field: decolonization works in the short term, but repeated or widespread use could erode the very tool being used.

How Long Colonization Lasts

If you have tested positive once, you might wonder how long MRSA sticks around. In a study that followed hospitalized patients over time, the median duration of colonization was about 33 months.²¹ Some people cleared the bacteria within a few months; others carried it for years. The strongest predictor of persistent colonization was the total amount of time the person had previously spent in hospitals. This makes sense: hospitals are where MRSA thrives, and repeated exposure keeps reseeding the nostrils.

For otherwise healthy people who pick up MRSA in the community, the duration tends to be shorter, though data on this group are thinner. Your body’s own nasal microbiome plays a role. Certain bacteria that naturally inhabit the nose, including some lactic acid bacteria, can suppress Staphylococcus aureus colonization, essentially outcompeting MRSA for space and nutrients.²² The composition of your nasal microbiome appears to be driven more by environmental factors than genetics, which suggests that hygiene habits, living conditions, and antibiotic exposure all shape how hospitable your nose is to MRSA.²³

Who Is Most Likely to Be Colonized

Not everyone faces the same risk of carrying MRSA nasally. Some risk factors are medical, and others are about your environment and daily habits. In a study of people experiencing homelessness, risk factors for nasal MRSA carriage included recent hospitalization, being on hemodialysis, heavy alcohol use, not showering daily, and frequent moves between shelters.²⁴ Among joint replacement patients, immunosuppression and kidney problems were independent predictors of nasal carriage.²⁵ In children, recent antibiotic use, recent hospitalization, living in crowded households, and having parents who smoke were all associated with MRSA nasal carriage.²⁶

The common thread is exposure opportunity plus a weakened ability to fight off colonization: hospitals, crowded settings, compromised immunity, disrupted skin or mucosal barriers, and recent antibiotics that may have wiped out the competing bacteria that normally keep MRSA in check.

Community-Acquired Versus Hospital-Acquired Strains

If you test positive outside of a hospital context, you may be carrying a community-associated MRSA strain rather than the older hospital-associated type, and the two are not the same. Community-associated MRSA strains tend to be more virulent and more easily transmitted between healthy people.²⁷ They cause different clinical problems, are often susceptible to a wider range of antibiotics, and spread rapidly through settings like athletic teams, military barracks, and households.²⁸ The skin and soft tissue infections they cause, boils and abscesses in particular, are the classic calling card.

The distinction has blurred somewhat over the past two decades, as community strains have increasingly been found inside hospitals. But from a treatment standpoint it still matters, because the antibiotic options differ between the two groups.

Contact Precautions and the Hospital Experience

A positive MRSA swab during a hospital stay often triggers contact precautions: you may be moved to a single room, healthcare workers will gown and glove before entering, and visitors may be asked to follow similar protocols. The rationale is to prevent transmission to other patients. There is evidence this works in outbreak settings and when compliance is high, with one study finding a 61% reduction in MRSA acquisition on wards that implemented active surveillance and contact precautions.²⁹

But the picture is not entirely straightforward. Reviews of the evidence have found that while contact precautions reduce transmission, they have not consistently been shown to reduce actual infection rates. And they come with unintended costs: healthcare providers spend less time with isolated patients, patient complaints increase, and there are documented psychological effects including anxiety and feelings of stigma.³⁰ Recent debate in the infectious disease world has questioned whether routine contact precautions for MRSA-colonized patients are still warranted in the era of universal gloving and improved hand hygiene, though no consensus has emerged.³¹

The Emotional Side of Being Labeled a Carrier

Something that clinical discussions often skip over is how it feels to be told you are carrying MRSA. Research on patient experiences of source isolation paints a mixed picture. Being put in isolation can cause anxiety, stress, and even depression, alongside a perception of receiving less attentive care.³² Many patients are confused about what MRSA actually is. In qualitative interviews, most people with MRSA were uncertain about how they acquired it and did not understand why isolation was necessary. About half considered MRSA “serious” despite not experiencing any symptoms from it.³³

If you have just received a positive result, the most practical thing to remember is that colonization is common, it usually does not lead to illness, and the precautions that follow are about protecting vulnerable people around you rather than about something being acutely wrong with you. Asking your care team to explain the specific steps they are recommending and why tends to reduce the anxiety considerably.

Pets and Household Spread

MRSA does not just pass between people. Dogs and cats can carry the same MRSA strains found in humans, and the types of clones identified in pets tend to match those circulating in humans in the same geographic area.³⁴ This does not mean your cat gave you MRSA or that you need to panic about your dog. But if you are a known carrier undergoing decolonization and the bacteria keep coming back, a veterinary check of household pets is something some infectious disease specialists recommend. The mouth, nose, and perineum are the primary colonization sites in animals, mirroring the pattern in humans.

When Universal Screening Makes Economic Sense

Not every hospital screens every patient. Whether universal MRSA nasal screening is cost-effective depends heavily on how common MRSA carriage is in that facility’s patient population. Economic analyses have found that the local prevalence of MRSA colonization is the strongest predictor of whether screening programs save money. Hospitals with higher MRSA rates are more likely to recoup the cost of testing through prevented infections and shorter antibiotic courses, while facilities with low prevalence may spend more on screening than they save.³⁵ This is why screening policies vary so much from one hospital to the next and why you might be swabbed at one facility but not another even in the same city.